Table 2.
Variance in preoperative clinicopathological parameters between patients with and without seminal vesicle involvement (SVI)
|
SVI present (n = 8) |
SVI absent (n = 116) |
Univariate |
Multivariate |
||
|---|---|---|---|---|---|
| P value | P value | Adjusted odds ratio (95% CI) | |||
| Mean age [years] |
63.6 ± 3.9 |
63.9 ± 5.1 |
0.725 |
|
|
| PSA [ng/ml] |
13.0 ± 8.1 |
8.7 ± 7.2 |
0.105 |
|
|
| Gleason score at biopsy |
8.1 ± 1.1 |
7.0 ± 1.0 |
0.005 |
|
|
| cT stage (n) |
|
|
0.153 |
|
|
| T1c |
5 (62.5%) |
94 (81.0%) |
|
|
|
| T2 |
3 (37.5%) |
15 (12.9%) |
|
|
|
| T3a |
0 (0%) |
7 (6.0%) |
|
|
|
| %positive cores |
31.0 ± 21.3 |
21.3 ±16.4 |
0.242 |
|
|
| TZ biopsy positive (n) |
7 (87.5%) |
35 (30.2%) |
0.002 |
0.023 |
12.99 (1.490-111.1) |
| Number of apex-positive (2–4/0–1) (n) |
3/5 |
26/90 |
0.278 |
|
|
| Number of middle-positive (2–4/0–1) (n) |
6/2 |
28/88 |
0.005 |
0.025 |
7.299 (1.312-40.00) |
| Number of base-positive (2–4/0–1) (n) | 4/4 | 23/93 | 0.067 | ||
PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middle, prostatic middle biopsy; base, prostatic base biopsy.